

Luc Biedermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7575591/publications.pdf>

Version: 2024-02-01

146
papers

13,427
citations

57631

44
h-index

22102

113
g-index

149
all docs

149
docs citations

149
times ranked

6846
citing authors

#	ARTICLE	IF	CITATIONS
1	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 560-571.	0.9	20
2	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
3	Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1729-1738.e1.	2.4	8
4	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2520-2533.	2.7	15
5	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
6	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210741.	1.4	5
7	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	2.4	57
8	Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis. <i>United European Gastroenterology Journal</i> , 2022, 10, 308-318.	1.6	17
9	Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme. <i>United European Gastroenterology Journal</i> , 2022, 10, 330-343.	1.6	11
10	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2514-2523.e2.	2.4	19
11	Lifting the Veil: The Quest for Noninvasive Biomarkers for the Accurate Diagnosis of Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1388-1389.	1.1	2
12	Food-induced immediate response of the esophagus? A newly identified syndrome in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 339-347.	2.7	22
13	How to approach adult patients with asymptomatic esophageal eosinophilia. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	9
14	Protein-losing enteropathy as precursor of inflammatory bowel disease: a review of the literature. <i>BMJ Case Reports</i> , 2021, 14, e238802.	0.2	1
15	Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110337.	1.4	6
16	Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 187-197.	0.8	1
17	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000514.	1.5	4
18	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	1

#	ARTICLE	IF	CITATIONS
19	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. <i>British Journal of Pharmacology</i> , 2021, 178, 3157-3175.	2.7	9
20	Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. <i>Colorectal Disease</i> , 2021, 23, 1444-1450.	0.7	19
21	Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 912-919.e2.	0.5	12
22	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 53-67.	1.9	16
23	Features of food-induced immediate response in the esophagus (FIRE) in a series of adult patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2893-2895.	2.7	8
24	Long-term immune-related adverse events after discontinuation of immunotherapy. <i>Immunotherapy</i> , 2021, 13, 735-740.	1.0	5
25	Eosinophilic esophagitis—established facts and new horizons. <i>Seminars in Immunopathology</i> , 2021, 43, 319-335.	2.8	25
26	Defer No Time, Delays Have Dangerous Ends (William Shakespeare). <i>Gastroenterology</i> , 2021, 161, 42-44.	0.6	2
27	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 773-780.	1.6	4
28	Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis?. <i>Dysphagia</i> , 2021, , 1.	1.0	0
29	Clinicopathologic Correlations in Eosinophilic Gastrointestinal Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3258-3266.	2.0	8
30	Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 1169-1193.	0.9	8
31	Fatigue in inflammatory bowel disease and its impact on daily activities. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 138-149.	1.9	25
32	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 1-10.	0.8	15
33	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. <i>BMC Gastroenterology</i> , 2021, 21, 310.	0.8	0
34	Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 727-730.	2.7	17
35	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2019-2029.e11.	2.4	64
36	Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 211-220.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding. <i>Digestion</i> , 2020, 101, 27-42.	1.2	27
38	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2654-2663.	1.1	4
39	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2456-2462.	2.4	2
40	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
41	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 1196-1207.	1.6	24
42	Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 159, 1672-1685.e5.	0.6	88
43	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095925.	1.4	7
44	Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis. <i>BMC Gastroenterology</i> , 2020, 20, 419.	0.8	4
45	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 170-179.	0.8	3
46	Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092728.	1.4	24
47	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1503-1511.	0.6	100
48	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628481989521.	1.4	2
49	Nutrition in Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 120-135.	1.2	59
50	Gender Differences in Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 98-104.	1.2	82
51	Complete Recovery of Immune Checkpoint Inhibitor-induced Colitis by Diverting Loop Ileostomy. <i>Journal of Immunotherapy</i> , 2020, 43, 145-148.	1.2	4
52	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2385-2386.	2.4	1
53	Editorial: anti-TNF therapy—a double-edged sword?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 822-823.	1.9	3
54	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986514.	1.4	20

#	ARTICLE	IF	CITATIONS
55	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS ONE, 2019, 14, e0210436.	1.1	26
56	Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology, 2019, 157, 74-86.e15.	0.6	170
57	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS ONE, 2019, 14, e0211554.	1.1	15
58	Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Digestive Diseases and Sciences, 2019, 64, 2231-2241.	1.1	49
59	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. PLoS ONE, 2019, 14, e0215738.	1.1	5
60	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2019, 17, 1477-1488.e10.	2.4	16
61	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1292-1301.	0.6	37
62	Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterology Journal, 2019, 7, 767-781.	1.6	67
63	Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 419-428.e6.	2.4	66
64	RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology, 2019, 156, 592-603.e10.	0.6	182
65	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. American Journal of Gastroenterology, 2019, 114, 116-126.	0.2	39
66	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1875771.	1.4	5
67	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. Inflammatory Bowel Diseases, 2018, 24, 1768-1779.	0.9	32
68	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 811-818.	0.6	88
69	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas, 2018, 110, 71-78.	1.0	25
70	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. European Journal of Gastroenterology and Hepatology, 2018, 30, 612-620.	0.8	30
71	Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms. American Journal of Gastroenterology, 2018, 113, 348-357.	0.2	32
72	Expression Patterns of TNF α , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	0.6	44

#	ARTICLE	IF	CITATIONS
73	Pharmacologic Treatment of Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 77-88.	0.6	12
74	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. <i>Digestive Diseases</i> , 2018, 36, 123-129.	0.8	14
75	Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 35-45.	0.6	18
76	Diagnosis and Treatment of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 154, 346-359.	0.6	110
77	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 25-29.	1.1	9
78	Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis— Current Concepts and Perspectives for Steroid Use. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e212.	1.3	31
79	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. <i>United European Gastroenterology Journal</i> , 2018, 6, 1007-1014.	1.6	14
80	Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1082-1090.	1.9	24
81	Medical and dietary treatments in eosinophilic esophagitis. <i>Current Opinion in Pharmacology</i> , 2018, 43, 139-144.	1.7	5
82	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
83	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56
84	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. <i>PLoS ONE</i> , 2018, 13, e0199664.	1.1	35
85	Sa1118 - Eosinophilic Esophagitis-Like Disease with Lack of Significant Esophageal Eosinophilia: Description of a New Disease Entity. <i>Gastroenterology</i> , 2018, 154, S-246.	0.6	1
86	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
87	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1399-1409.	0.6	40
88	Minimally invasive biomarker studies in eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 218-228.	0.5	55
89	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. <i>Swiss Medical Weekly</i> , 2018, 148, w14599.	0.8	27
90	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. <i>BMJ Open</i> , 2017, 7, e013477.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. <i>United European Gastroenterology Journal</i> , 2017, 5, 335-358.	1.6	718
92	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. <i>Digestive and Liver Disease</i> , 2017, 49, 268-272.	0.4	3
93	A Symptomatic Coffee Bean: Acute Sigmoid Volvulus. <i>Case Reports in Gastroenterology</i> , 2017, 11, 348-351.	0.3	10
94	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 131-138.	0.8	13
95	Vancomycin in Very-Early Onset Inflammatory Bowel Disease-Dysbiosis: Fight Fire with Fire?. <i>Digestion</i> , 2017, 95, 327-328.	1.2	0
96	Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept. <i>American Journal of Gastroenterology</i> , 2017, 112, 1527-1535.	0.2	105
97	Effects of oral antibiotics and isotretinoin on the murine gut microbiota. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 342-351.	1.1	27
98	Fistulizing Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e106.	1.3	24
99	Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECs). <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 163-170.	0.8	10
100	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. <i>PLoS ONE</i> , 2017, 12, e0185193.	1.1	54
101	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 172-181.	0.8	10
102	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2016, 11, e0154817.	1.1	71
103	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2016, 11, e0155218.	1.1	31
104	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. <i>PLoS ONE</i> , 2016, 11, e0156666.	1.1	104
105	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. <i>PLoS ONE</i> , 2016, 11, e0160215.	1.1	7
106	Long-term changes of bacterial and viral compositions in the intestine of a recovered <i>Clostridium difficile</i> patient after fecal microbiota transplantation. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000448.	0.5	50
107	Prediction of low bone mineral density in patients with inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2016, 4, 669-676.	1.6	21
108	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. <i>Case Reports in Gastroenterology</i> , 2016, 10, 113-119.	0.3	5

#	ARTICLE	IF	CITATIONS
109	Celiac disease diagnosis still significantly delayed – Doctor's but not patients' delay responsive for the increased total delay in women. <i>Digestive and Liver Disease</i> , 2016, 48, 1148-1154.	0.4	30
110	Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. <i>United European Gastroenterology Journal</i> , 2016, 4, 97-104.	1.6	44
111	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	0.6	251
112	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. <i>Endoscopy</i> , 2016, 48, 256-262.	1.0	45
113	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic esophagitis. <i>Gut</i> , 2016, 65, 524-531.	6.1	279
114	Acute Herpes Simplex Viral Esophagitis Occurring in 5 Immunocompetent Individuals With Eosinophilic Esophagitis. <i>ACG Case Reports Journal</i> , 2016, 3, 165-168.	0.2	61
115	Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? – a patient survey. <i>Nutrition Journal</i> , 2015, 14, 78.	1.5	14
116	High Rates of Smoking Especially in Female Crohn's Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation – Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 819-829.	0.6	52
117	New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. <i>Case Reports in Gastroenterology</i> , 2015, 9, 106-112.	0.3	7
118	Exercise-induced Chest Pain: An Atypical Manifestation of Eosinophilic Esophagitis. <i>American Journal of Medicine</i> , 2015, 128, 196-199.	0.6	16
119	The intestinal microbiota: its role in health and disease. <i>European Journal of Pediatrics</i> , 2015, 174, 151-167.	1.3	144
120	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.2	44
121	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	0.6	221
122	Smoking Cessation Alters Intestinal Microbiota. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1496-1501.	0.9	142
123	Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. <i>Digestive and Liver Disease</i> , 2014, 46, 1066-1071.	0.4	4
124	Update on basic and clinical aspects of eosinophilic esophagitis. <i>Gut</i> , 2014, 63, 1355-1363.	6.1	29
125	Reply. <i>Gastroenterology</i> , 2014, 146, 1426-1427.	0.6	0
126	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 191-199.	0.6	37

#	ARTICLE	IF	CITATIONS
127	Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent Manner. <i>Gastroenterology</i> , 2013, 145, 1230-1236.e2.	0.6	580
128	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – An open pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 271-279.	0.6	106
129	Nutcracker Esophagus. <i>New England Journal of Medicine</i> , 2013, 368, e25.	13.9	0
130	Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans. <i>PLoS ONE</i> , 2013, 8, e59260.	1.1	305
131	Environmental Factors and Their Impact on the Intestinal Microbiota: A Role for Human Disease?. <i>Digestive Diseases</i> , 2012, 30, 20-27.	0.8	10
132	The Way to a Man's Stomach Is Through His Heart. <i>Gastroenterology</i> , 2012, 142, 212-413.	0.6	5
133	Pregnancy and Breastfeeding in Inflammatory Bowel Disease. <i>Digestion</i> , 2012, 86, 45-54.	1.2	21
134	The Natural History and Complications of Eosinophilic Esophagitis. <i>Thoracic Surgery Clinics</i> , 2011, 21, 575-587.	0.4	45
135	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
136	Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1349-1350.e5.	1.5	313
137	Long-Term Budesonide Maintenance Treatment Is Partially Effective for Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 400-409.e1.	2.4	348
138	Budesonide Is Effective in Adolescent and Adult Patients With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2010, 139, 1526-1537.e1.	0.6	477
139	Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. <i>American Journal of Gastroenterology</i> , 2010, 105, 1062-1070.	0.2	277
140	What's new in the diagnosis and therapy of eosinophilic esophagitis?. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 366-371.	1.0	10
141	Eosinophilic Esophagitis: Analysis of Food Impaction and Perforation in 251 Adolescent and Adult Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 598-600.	2.4	217
142	Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 865-869.	0.8	174
143	Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and Treatment. <i>Gastroenterology</i> , 2007, 133, 1342-1363.	0.6	1,547
144	Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1090-1092.	1.5	184

#	ARTICLE	IF	CITATIONS
145	Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. <i>Gastroenterology</i> , 2003, 125, 1660-1669.	0.6	673
146	Idiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 954-961.	1.5	511